An integrative transcriptomic and network analysis linked carboplatin with four molecular targets in melanoma: CDKN1A, BRCA1, PTEN and AKT1. The researchers compared three independent gene-expression datasets and identified 194 genes differentially expressed across all three. They then combined protein–protein interaction analysis, drug–gene matching through DGIdb and experiments in B16F0 melanoma cells to examine the selected targets.

Carboplatin produced dose- and time-dependent cytotoxicity in the cells, with an IC₅₀ of approximately 17 µM after 48 hours. These findings offer a mechanistic model for an established anticancer drug, but the reported evidence does not establish clinical benefit in patients. Melanoma is described in the study as an aggressive malignancy with high metastatic potential and frequent resistance to standard therapies.

The authors aimed to identify molecular markers associated with melanoma progression and clarify how clinically used agents might counteract tumor-specific dysregulation. Rather than evaluating one gene or compound in isolation, the study integrated comparative gene-expression profiling with network analysis and laboratory experiments. The three analyzed datasets were processed comparatively to determine which differentially expressed genes were shared, producing a set of 194 overlapping genes.

Those genes were enriched in pathways central to tumor progression, although the supplied abstract does not identify the individual pathways or the statistical thresholds used to select them. The researchers constructed a protein–protein interaction network from the overlapping genes and used the Maximal Clique Centrality algorithm to prioritize hub genes occupying important network positions. This step was intended to identify regulatory nodes relevant to melanoma biology rather than simply rank genes by expression magnitude.

In parallel, DGIdb analysis identified carboplatin as a multi-target compound associated with CDKN1A, BRCA1, PTEN and AKT1. The analysis does not by itself show that the drug acts directly on all four targets in human tumors. Experimental testing focused on B16F0 melanoma cells.

Exposure to carboplatin caused cytotoxicity that increased with both dose and exposure time, and the reported half-maximal inhibitory concentration was approximately 17 µM at 48 hours. Reverse-transcription quantitative PCR measured increased expression of CDKN1A, BRCA1 and PTEN alongside reduced expression of AKT1. The authors interpret this pattern as evidence consistent with activation of DNA-damage-response pathways and reinforcement of tumor-suppressive signaling.

The study’s main contribution is a combined computational and cell-based framework for investigating an established anticancer drug through several transcriptomically relevant targets. The shared-gene analysis, interaction network, hub prioritization and DGIdb matching provide a testable model, while the B16F0 experiments show that carboplatin can alter the expression of the selected genes under laboratory conditions. The reported results do not provide evidence that the expression changes predict survival, recurrence or treatment response in people, nor do they establish that CDKN1A, BRCA1, PTEN or AKT1 can guide clinical selection of carboplatin.

Instead, the work identifies mechanistic associations and target-specific responses that can inform further biomarker and translational research. Its conclusions should remain bounded by the analyzed datasets and the experimental cell model, because the supplied evidence does not report patient outcomes or establish clinical efficacy for the proposed biomarker strategy.

Subject of Research: Computational and cell-based analysis of carboplatin-associated molecular targets in melanoma

Article Title: Integrative transcriptomic and network analysis elucidates the multi-target molecular mechanisms of carboplatin in melanoma

Article References: Shahriarizade, M., Ahmadi, S. M., & Firouzjaei, A. A. (2026). Integrative transcriptomic and network analysis elucidates the multi-target molecular mechanisms of carboplatin in melanoma. Medical Oncology, 43(11), Article 349. https://doi.org/10.1007/s12032-026-03460-x

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03460-x

Keywords: melanoma, carboplatin, transcriptomics, network analysis, drug-gene interactions, B16F0 cells, DNA damage response, biomarker discovery, CDKN1A, BRCA1, PTEN, AKT1